Akari Therapeutics, Plc
AKTX
$11.05
$0.090.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.41% | 1.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.85% | 12.43% | |||
| Operating Income | -26.85% | -12.43% | |||
| Income Before Tax | 68.61% | -193.77% | |||
| Income Tax Expenses | -- | -1,110.59% | |||
| Earnings from Continuing Operations | 66.75% | -172.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.75% | -172.84% | |||
| EBIT | -26.85% | -12.43% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 72.44% | -98.51% | |||
| Normalized Basic EPS | -18.86% | -144.31% | |||
| EPS Diluted | 72.44% | -98.51% | |||
| Normalized Diluted EPS | -18.86% | -144.31% | |||
| Average Basic Shares Outstanding | 20.68% | 37.44% | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||